TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04485117

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral Index Monitor
Description: Bispectral Index (BIS) sensor electrodes are applied over the patient's forehead after cleaning the forehead thoroughly with an alcohol swab.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral Index Monitor
Description: Bispectral Index (BIS) sensor electrodes are applied over the patient's forehead after cleaning the forehead thoroughly with an alcohol swab.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway
Description: Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway
Description: Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia is induced inhalationally by face mask with 8% sevoflurane in 100% oxygen, then decreased to 2-3% in 40% oxygen thoroughout the operation for maintenance of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthesia is induced by propofol (2mg/kg), then maintained using an infusion of fixed concentration (10-15 mg/kg/h) as titrated by the anesthesiologist .
Study: NCT03837353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: DKN-01 is a large molecular weight protein that will be given as a flat dose on a Days 1 and 15 of a 21-day cycle in Dose-Escalation Cohort 1A and Dose-Expansion Cohort 1B. DKN-01 will be given on Days 1 and 15 on a 28-day cycle in Dose-Escalation Cohort 2A and Dose-Expansion Cohort 2B. The dose of DKN-01 will be administered as an intravenous (IV) infusion over 60 (±) 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: DKN-01 is a large molecular weight protein that will be given as a flat dose on a Days 1 and 15 of a 21-day cycle in Dose-Escalation Cohort 1A and Dose-Expansion Cohort 1B. DKN-01 will be given on Days 1 and 15 on a 28-day cycle in Dose-Escalation Cohort 2A and Dose-Expansion Cohort 2B. The dose of DKN-01 will be administered as an intravenous (IV) infusion over 60 (±) 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: DKN-01 is a large molecular weight protein that will be given as a flat dose on a Days 1 and 15 of a 21-day cycle in Dose-Escalation Cohort 1A and Dose-Expansion Cohort 1B. DKN-01 will be given on Days 1 and 15 on a 28-day cycle in Dose-Escalation Cohort 2A and Dose-Expansion Cohort 2B. The dose of DKN-01 will be administered as an intravenous (IV) infusion over 60 (±) 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: DKN-01 is a large molecular weight protein that will be given as a flat dose on a Days 1 and 15 of a 21-day cycle in Dose-Escalation Cohort 1A and Dose-Expansion Cohort 1B. DKN-01 will be given on Days 1 and 15 on a 28-day cycle in Dose-Escalation Cohort 2A and Dose-Expansion Cohort 2B. The dose of DKN-01 will be administered as an intravenous (IV) infusion over 60 (±) 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered as an IV infusion over approximately 60 (±15) minutes on day 1 of a 21-day cycle in Cohorts 1A and 1B. In Cohort 1A, docetaxel must be dosed at 75 mg/m2 on cycle 1 day 1. Docetaxel can be dosed at 75 mg/m2 or 60 mg/m2 in subsequent cycles depending on clinical discretion and dose modification guidelines. Regardless of dose, docetaxel must be dosed in 21-day cycles. In Cohort 1B, cycle 1 day 1 dosing of docetaxel will either be 75 mg/m2 or 60 mg/m2 depending on clinical discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered as an IV infusion over approximately 60 (±15) minutes on day 1 of a 21-day cycle in Cohorts 1A and 1B. In Cohort 1A, docetaxel must be dosed at 75 mg/m2 on cycle 1 day 1. Docetaxel can be dosed at 75 mg/m2 or 60 mg/m2 in subsequent cycles depending on clinical discretion and dose modification guidelines. Regardless of dose, docetaxel must be dosed in 21-day cycles. In Cohort 1B, cycle 1 day 1 dosing of docetaxel will either be 75 mg/m2 or 60 mg/m2 depending on clinical discretion.
Study: NCT03444194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: liver biopsy
Description: Liver biopsy of neoplastic tissue and normal liver tissue.
Study: NCT03294928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive increasing of PEEP level.
Description: four-step measurements of central artery blood pressure evaluating contour wave analysis during a progressive increasing of PEEP level First step (Baseline) Subjects spontaneously breathe in air at atmospheric pressure during applanation tonometry.~Second step (PEEP=5 cm H2O) Applanation tonometry was performed during the application of PEEP = 5 cmH2O (Oxygen flow = 8lt.- Air flow = 10 lt.).~Third step (PEEP= 10 cm H2O) Applanation tonometry was performed during the application of PEEP = 10 cmH2O (Oxygen flow = 15lt.- Air flow = 20 lt.).~Fourth step (Recovery) Subjects spontaneously rebreathe air at atmospheric pressure during applanation tonometry.
Study: NCT04198896

Intervention type: OTHER
Intervention: incidece of cancers
Description: With a continuous surveillance system to track all subsequent incidents of cardiovascular diseases and/or non-cardiovascular diseases via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified

Intervention type: OTHER
Intervention: incidece of cancers
Description: With a continuous surveillance system to track all subsequent incidents of cardiovascular diseases and/or non-cardiovascular diseases via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified
Study: NCT04694326

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c
Description: The participants' age, sex, education level, known diseases, unit of hospitalization and inpatient diagnosis were questioned and recorded. Height, weight and waist circumference measurements were taken. Fasting blood sugar and HbA1c measurements were made
Study: NCT03082664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO Single Use Negative Pressure Wound Therapy
Description: The PICO device will be placed over the closed cesarean section incision.
Study: NCT00000607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left ventricular assist device
Description: A type of implantable heart pump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical therapy
Description: (non-experimental) One possibility in handling Heart failure effectively is optimal medicine therapy. The most popular treatment medications at present are ACE Inhibitors and Beta Blockers. The result is the heart being able to pump more effectively and allowing blood to circulate freely.
Study: NCT03520868

Intervention type: DIAGNOSTIC_TEST
Intervention: Monitoring Anti Factor Xa level
Description: Each patient will have baseline Anti-Factor Xa assay checked. During the procedure, Anti-Factor Xa assay is checked concurrently with ACT after heparin bolus and infusion.

Intervention type: DIAGNOSTIC_TEST
Intervention: Monitoring Anti Factor Xa level
Description: Each patient will have baseline Anti-Factor Xa assay checked. During the procedure, Anti-Factor Xa assay is checked concurrently with ACT after heparin bolus and infusion.

Intervention type: DIAGNOSTIC_TEST
Intervention: Monitoring Anti Factor Xa level
Description: Each patient will have baseline Anti-Factor Xa assay checked. During the procedure, Anti-Factor Xa assay is checked concurrently with ACT after heparin bolus and infusion.

Intervention type: DIAGNOSTIC_TEST
Intervention: Monitoring Anti Factor Xa level
Description: Each patient will have baseline Anti-Factor Xa assay checked. During the procedure, Anti-Factor Xa assay is checked concurrently with ACT after heparin bolus and infusion.
Study: NCT00932230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KinesioTape
Description: An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
Study: NCT03301532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Dietary supplementation with triheptanoin
Study: NCT01929031

Intervention type: DRUG
Group type: OTHER
Intervention: ibuprofen + caffeine
Description: FDC tablet

Intervention type: DRUG
Group type: OTHER
Intervention: ibuprofen
Description: tablet.

Intervention type: DRUG
Group type: OTHER
Intervention: ibuprofen
Description: tablet

Intervention type: DRUG
Group type: OTHER
Intervention: caffeine
Description: tablet

Intervention type: DRUG
Group type: OTHER
Intervention: ibuprofen + caffeine
Description: Fixed Dose Combination (FDC) tablet

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: tablet

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: tablet

Intervention type: DRUG
Group type: OTHER
Intervention: caffeine
Description: tablet

Intervention type: DRUG
Group type: OTHER
Intervention: ibuprofen
Description: tablet

Intervention type: DRUG
Group type: OTHER
Intervention: ibuprofen + caffeine
Description: FDC tablet
Study: NCT04016792

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg SPN-812
Description: 200 mg SPN-812 will be administered once daily and compared to Placebo
Study: NCT02035839

Intervention type: DEVICE
Group type: OTHER
Intervention: Target Temperature Management of 34°C
Description: In hospital target temperature management to achieve core body temperature of 34°C for 24 hours.

Intervention type: DEVICE
Group type: OTHER
Intervention: Target Temperature Management of 32°C
Description: In hospital target temperature management to achieve core body temperature of 32°C for 24 hours.

Intervention type: DEVICE
Group type: OTHER
Intervention: Target Temperature Management of 33°C
Description: In hospital target temperature management to achieve core body temperature of 33°C for 24 hours.
Study: NCT03864042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion immediate release (IR)
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: taken orally
Study: NCT03483389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol, Ethyl
Description: Randomized within-subjects design

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol, Ethyl - placebo
Description: Randomized within-subjects design

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol, Ethyl - placebo
Description: Randomized within-subjects design

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol, Ethyl - placebo
Description: Randomized within-subjects design
Study: NCT04224519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV batch 1
Description: Type I 30 DU, Type II 32 DU, Type III 45 DU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV batch 2
Description: Type I 30 DU, Type II 32 DU, Type III 45 DU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV batch 3
Description: Type I 30 DU, Type II 32 DU, Type III 45 DU
Study: NCT00328172

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 1356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 dose 3 once daily
Description: BI 1356 dose 3 once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 dose 2 once daily
Description: BI 1356 dose 2 once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 dose 1 once daily
Description: BI 1356 dose 1 once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin
Study: NCT02782910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone-Based Ambulatory Assessment, Feedback via physician
Description: Participants in the experimental condition SBAA+ will be contacted by their treating physician, once the predefined threshold for Smartphone activity is exceeded.
Study: NCT02850588

Intervention type: PROCEDURE
Intervention: Transcarotid artery revascularization
Description: Direct implantation of a stent into the carotid artery via a surgical incision in the neck combined with blood flow reversal in the carotid artery during stent placement

Intervention type: PROCEDURE
Intervention: Carotid endarterectomy
Description: Removal of carotid atherosclerotic plaque (endarterectomy) via a surgical incision in the neck
Study: NCT03573492

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Type of teaching being assigned to student arms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Type of teaching being assigned to student arms
Study: NCT03563092

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Inguinal Hernia (TEP/TAPP) Surgery
Description: Standardized minimally invasive approach to inguinal hernia repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Inguinal Hernia (TEP/TAPP) Surgery
Description: Standardized minimally invasive approach to inguinal hernia repair
Study: NCT01344148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH RIF Rifb PZA EMB AZT 3TC D4T EFV
Description: The first cohort study is the patients begin HAART after anti-TB therapy 2 weeks,and the second cohort is after 8 weeks begin HAART. Anti-TB therapy program is 2HREZ-4HRifb. And the first line of HAART plan is AZT+3TC+EFV and the second line plan is D4T+3TC+EFV.If begin with HAART and the RIF will change to Rifb.
Study: NCT06556316

Intervention type: BEHAVIORAL
Intervention: Social Cognitive Communication Program
Description: An 11 week group intervention targeting social and cognitive-communication abilities

Intervention type: BEHAVIORAL
Intervention: Social Cognitive Communication Program
Description: An 11 week group intervention targeting social and cognitive-communication abilities

Intervention type: BEHAVIORAL
Intervention: Social Cognitive Communication Program
Description: An 11 week group intervention targeting social and cognitive-communication abilities

Intervention type: BEHAVIORAL
Intervention: Social Cognitive Communication Program
Description: An 11 week group intervention targeting social and cognitive-communication abilities

Intervention type: BEHAVIORAL
Intervention: Social Cognitive Communication Program
Description: An 11 week group intervention targeting social and cognitive-communication abilities

Intervention type: DEVICE
Intervention: Non-Invasive Brain Stimulation with tDCS
Description: 20 minute tDCS intervention as a non-invasive neuromodulation treatment

Intervention type: DEVICE
Intervention: Non-Invasive Brain Stimulation with tDCS
Description: 20 minute tDCS intervention as a non-invasive neuromodulation treatment
Study: NCT00994097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed: 500 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed: 500 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
Study: NCT00306397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Sirolimus perorally following kidney transplantation, randomisation after protocol biopsy at months three to a) Sirolimus - MF- or b) low dose tacrolimus - sirolimus -MMF -

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Sirolimus perorally following kidney transplantation, randomisation after protocol biopsy at months three to a) Sirolimus - MF- or b) low dose tacrolimus - sirolimus -MMF -
Study: NCT01641575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CO-1.01 and Cisplatin
Description: CO-1.01 administered over 30 minutes followed by 75 mg/ml Cisplatin over 2 hours (both intravenous) on C1D1. CO-1.01 administered intravenously over 30 minutes on C1D8.
Study: NCT04437186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery program
Description: The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the Pathways to Recovery (PTR): A Strengths Recovery Self-Help Workbook (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
Study: NCT05282329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating Current Stimulation (tACS)-active
Description: Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. daily tACS sessions were scheduled in a 5-day sequence for four consecutive weeks, and each session lasted 20minutes. Participants were administered 2 mA alternating current delivered with gamma frequency, delivered over the temporal lobe.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Alternating Current Stimulation (tACS)-sham
Description: Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. Controls received sham stimulations with the same protocol.
Study: NCT03400878

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG-Japan
Description: One dose of 0.05 ml BCG-Japan vaccine applied to the left deltoid region.
Study: NCT03794349

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dinutuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine Hydrochloride
Description: Given PO or via NG or G tube

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sargramostim
Description: Given SC or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given PO or via NG or G tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO or via NG or G tube
Study: NCT00854360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate HFA Nasal Aerosol
Description: Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate HFA Nasal Aerosol
Description: Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate HFA Nasal Aerosol
Description: Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
Study: NCT03400878

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG-Russia
Description: One dose of 0.05 ml BCG-Russia vaccine applied to the left deltoid region.
Study: NCT04034628

Intervention type: DEVICE
Intervention: Peritoneal Catheter Insertion - Laparoscopic
Description: Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
Study: NCT00854360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: HFA Vehicle Aerosol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: HFA Vehicle Aerosol
Study: NCT04088396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Administered SC